This article is more than 5 years old. Information may no longer be current.
Corneal neovascularization may respond to subconjunctival treatment with anti-VEGF therapy
Click Here to Manage Email Alerts
BOSTON — Anti-VEGF therapy is a reasonable approach to the treatment of corneal neovascularization, according to a speaker.
 Allan R. Slomovic |
Since its introduction into ophthalmic practice, Avastin (bevacizumab, Genentech) has been studied in 51 different angiogenic conditions, Allan R. Slomovic, MD, said at the World Cornea Congress preceding the American Society of Cataract and Refractive Surgery meeting. Bevacizumab injection, and anti-VEGF in general, has gained popularity in treating a vast array of eye conditions because of the importance of VEGF in signaling the formation of new blood vessels, Dr. Slomovic said.
In a study of 10 consecutive eyes with corneal neovascularization treated with subconjunctival bevacizumab, Dr. Slomovic said that seven patients demonstrated partial regression of vessels and three patients had no response to therapy. However, "centricity of the vessels did not react to the Avastin injection," he said.
While the sample size is small, Dr. Slomovic said the outcomes are comparable to those found in 42 published studies found in a literature search that reported on bevacizumab use in corneal neovascularization.
Dr. Slomovic said he performed a second study on bevacizumab for treatment of pterygium that found no benefit to patients after injection.
Follow OSNSuperSite.com
on Twitter.